Valuation Merck & Co., Inc.

Stocks

Market Closed - NYSE Other stock markets 01:32:41 10/06/2026 am IST			After hours 05:30:00 am
119.60 ^USD	+0.07%		119.24	-0.30%

09/06	Merck & Co., Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM
09/06	What Bundibugyo Ebola vaccines and treatments are under development	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,93,588	2,81,302	2,76,259	2,51,648	2,61,258	2,95,391	-	-
Change	-	45.31%	-1.79%	-8.91%	3.82%	13.06%	-	-
Enterprise Value (EV) ¹	2,18,594	2,98,801	3,04,221	2,75,517	2,96,032	3,31,770	3,18,569	3,02,324
Change	-	36.69%	1.81%	-9.44%	7.45%	12.07%	-3.98%	-5.1%
P/E ratio	14.9x	19.4x	779x	14.8x	14.5x	53.4x	14.4x	12.5x
PBR	5.07x	6.12x	7.34x	5.44x	5.01x	6.07x	5.03x	4.14x
PEG	-	1.7x	-8x	0x	1.81x	-0.8x	0x	0.8x
Capitalization / Revenue	3.97x	4.75x	4.6x	3.92x	4.02x	4.42x	4.21x	3.9x
EV / Revenue	4.49x	5.04x	5.06x	4.29x	4.55x	4.96x	4.54x	3.99x
EV / EBITDA	10.5x	11.3x	30.2x	9.88x	9.08x	20.2x	9.49x	8.31x
EV / EBIT	12.4x	13.3x	49x	11.8x	11.1x	28x	11.1x	9.52x
EV / FCF	25.2x	20.3x	33.3x	15.2x	24x	28.3x	14x	12.1x
FCF Yield	3.97%	4.92%	3.01%	6.57%	4.18%	3.53%	7.17%	8.3%
Dividend per Share ²	2.64	2.8	2.96	3.12	3.28	3.344	3.463	3.674
Rate of return	3.44%	2.52%	2.72%	3.14%	3.12%	2.8%	2.9%	3.07%
EPS ²	5.14	5.71	0.14	6.74	7.28	2.241	8.312	9.604
Distribution rate	51.4%	49%	2,114%	46.3%	45.1%	149%	41.7%	38.3%
Net sales ¹	48,704	59,283	60,115	64,168	65,011	66,848	70,153	75,734
EBITDA ¹	20,910	26,431	10,083	27,897	32,617	16,449	33,575	36,383
EBIT ¹	17,696	22,522	6,211	23,398	26,779	11,837	28,738	31,758
Net income ¹	13,049	14,519	365	17,117	18,254	5,556	20,425	23,378
Net Debt ¹	25,006	17,499	27,962	23,869	34,774	36,379	23,178	6,933
Reference price ²	76.64	110.95	109.02	99.48	105.26	119.60	119.60	119.60
Nbr of stocks (in thousands)	25,25,944	25,35,396	25,34,023	25,29,636	24,82,023	24,69,824	-	-
Announcement Date	03/02/22	02/02/23	01/02/24	04/02/25	03/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
MERCK & CO., INC.	53.36x	4.96x	20.17x	2.8%	30TCr
MERCK KGAA	23.34x	3.21x	11.41x	1.68%	6.94TCr
HALOZYME THERAPEUTICS, INC.	10.62x	5.46x	8.4x	-	847.85Cr
KYOWA KIRIN CO., LTD.	15.08x	1.89x	6.47x	2.9%	763.51Cr
SK BIOPHARMACEUTICALS CO., LTD.	23.5x	6.95x	19x	-.--%	470.6Cr
YUHAN CORPORATION	42.59x	2.41x	29.38x	0.72%	374.06Cr
BETTA PHARMACEUTICALS CO., LTD.	27.35x	5.25x	15.01x	-	317.65Cr
SUPERNUS PHARMACEUTICALS, INC.	105.37x	-	-	-.--%	265.01Cr
Average	37.65x	4.30x	15.69x	1.35%	4.94TCr
Weighted average by Cap.	46.11x	4.61x	18.13x	2.52%